Goldman Sachs initiated coverage of UnitedHealth (UNH) with a Buy rating and $406 price target The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- ‘Load Up Ahead of October 28,’ Says Analyst About UnitedHealth (UNH) Stock
- Clover Health ‘loses big’ in CMS star ratings, says Leerink
- Mizuho, Barclays Boost UnitedHealth Stock (UNH) Price Target on Optimism Ahead of Q3 Earnings
- ‘Keep Buying,’ Affirm Several Analysts about UnitedHealth Group (UNH) Ahead of Q3
- UnitedHealth price target raised to $430 from $300 at Mizuho